An Open Label, Single Centre Study to Investigate the Metabolic Profile of Dalcetrapib After a Single Oral Dose in Healthy Male Subjects.
Latest Information Update: 19 Dec 2019
At a glance
- Drugs Dalcetrapib (Primary)
- Indications Atherosclerosis
- Focus Pharmacokinetics
- Sponsors Roche
- 16 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Nov 2011 New trial record